TITLE

Tratamiento de la anorexia urémica con acetato de megestrol

AUTHOR(S)
Lucas, M. Fernández; Teruel, J. L.; Burguera, V.; Sosa, H.; Rivera, M.; Palomares, J. R. Rodríguez; Marcén, R.; Quereda, C.
PUB. DATE
December 2010
SOURCE
Nefrologia;2010, Vol. 30 Issue 6, p646
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Anorexia is a common disorder in patients treated with regular hemodialysis and a contributing factor of malnutrition. The aim of this study was to evaluate the effectiveness of megestrol acetate, an appetite stimulant used in cancer patients as a treatment for anorexia in dialysis patients. Material and methods: In 2009, 16 patients in our hemodialysis unit, three with diabetes mellitus were treated with megestrol (160 mg/day single dose) for anorexia defined as a Likert scale of Appetite. The pattern and dialysis dose were not changed during the study. Results: In the third month of treatment is aimed, in the total group, an increase of dry weight (60.8 vs. 58.9 kg, p <.01), concentration of albumin (4.02 vs 3.8 g/dl, p <.05), creatinine concentration (9.73 vs. 8.26 mg/dl, p <.01) and protein catabolic rate (1.24 vs. 0.97 g/kg/day, p <0001). Non significant variations in the concentration of hemoglobin, erythropoietin dose, and concentration of lipids were found. One patient with diabetes mellitus had to increase the dose of insulin and two other patients have had some mild hyperglycemia. Megestrol acetate did not suppress the secretion of pituitary sex hormones, but in 3 of 10 patients studied was found inhibition of ACTH secretion. The response was not homogeneous: a patient did not respond and reduced its dry in weight, 5 weight gain was quiet (less than 1 kg) and the remaining ten the response was good with an increase in dry weight ranged between 1.5 and 5.5 kg. Conclusions: Megestrol acetate can improve appetite and nutritional parameters in patients treated with periodic hemodialysis who report anorexia. Megestrol acetate can induce hyperglycemia and inhibit the secretion of ACTH in some patients. These side effects should be assessed when given this treatment.
ACCESSION #
56947147

 

Related Articles

  • Treatment of uraemic anorexia with megestrol acetate. Lucas, M. Fernández; Teruel, J. L.; Burguera, V.; Sosa, H.; Rivera, M.; Palomares, J. R. Rodríguez; Marcén, R.; Quereda, C. // Nefrologia;2010, Vol. 30 Issue 6, p646 

    Background: Anorexia is a common disorder in patients treated with regular hemodialysis and a contributing factor of malnutrition. The aim of this study was to evaluate the effectiveness of megestrol acetate, an appetite stimulant used in cancer patients as a treatment for anorexia in dialysis...

  • 노년기 식욕촉진 약물요법. 윤 종 률 // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Nov2015, Vol. 58 Issue 11, p1027 

    Anorexia is one of the most common issues in older patients. Although there is a tendency for loss of appetite in older persons due to decreased physical activity and reduced resting metabolic rate, this physiological anorexia of aging can easily develop into progressive anorexia and weight...

  • Intensive Psychotherapy of Former Anorexic Individuals. Bemporad, Jules R.; Ratey, John // American Journal of Psychotherapy;Oct1985, Vol. 39 Issue 4, p454 

    Reports on the intensive psychotherapy of six recovered anorexic female adults. Premorbid parental and familial interaction and particular difficulties surrounding the onset of the anorexic illness; Description of persistent personality problems, difficulties in relationships and characteristic...

  • Anorexia not just a 'girl' problem.  // Asian Pacific Post;8/14/2008, p18 

    The article presents findings of a survey on the number of men being treated for anorexia and eating disorders in Great Britain.

  • Novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer. Lozano, Ramon Herreros; Jofre, Irene Serrat // Palliative Medicine;Oct2002, Vol. 16 Issue 6, p548 

    Focuses on the novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer. Alleged improvement in anorexia patients.

  • Successful treatment of anorexia with a combination of high-dose olanzapine, fluoxetine and mirtazapine. Fountoulakis, K. N.; Iacovides, A.; Siamouli, M.; Koumaris, V.; Kaprinis, G. S. // International Journal of Clinical Pharmacology & Therapeutics;2006, Vol. 44 Issue 9, p452 

    A letter to the editor is presented in response to the article about the treatment of anorexia with a combination of high dose olanzapine, fluoxetine and mirtazapine, published in the 1993 issue.

  • Unimed fattens marketshare with anti-anorexia medication. Oloroso Jr., Arsenio // Crain's Chicago Business;6/12/95, Vol. 18 Issue 24, p40 

    Focuses on drug maker Unimed Pharmaceuticals Inc. Development of anti-anorexia medication, Marinol; 1994 sales revenues and profits; Efforts to acquire or develop prescription pharmaceuticals to treat AIDS and cancer; Plans to enter the drug in clinical trials.

  • Acute gastric dilatation in anorexia nervosa.  // British Medical Journal;8/20/1977, Vol. 2 Issue 6085, p499 

    Examines the cause of acute gastric dilatation in anorexia nervosa in Great Britain. Details on gastric dilatation; Reference to the study in a man with anorexia; Development of gastric dilatation.

  • A second chance.  // Shape;Jul97, Vol. 16 Issue 11, p72 

    Focuses on the measures taken by Ohio resident, Adrienne Kistner to recover from the experience with anorexia. Background information on Kistner; Details on Kistner's experience with anorexia; Measures taken by Kistner to improve her personal fitness. INSET: Adrienne Kistner..

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics